Navigation Links
Chimerix to Present at Two Upcoming Investor Conferences
Date:11/12/2009

RESEARCH TRIANGLE PARK, N.C., Nov. 12 /PRNewswire/ -- Chimerix, Inc., a biopharmaceutical company advancing orally-available antiviral therapeutics to address life-threatening diseases, announced today that Kenneth I. Moch, Chief Operating Officer, will present a corporate overview at two upcoming investor conferences. Mr. Moch will discuss the company's technology assets and pipeline, including CMX001, a broad-spectrum antiviral being developed for the treatment of BK virus and cytomegalovirus in immunocompromised transplant patients and as a biodefense countermeasure in the event of a smallpox release.

Mr. Moch will speak at the Lazard Capital Markets 6th Annual Healthcare Conference on Wednesday, November 18, 2009 at 9:30 a.m. ET and at the Piper Jaffray 21st Annual Health Care Conference on Tuesday, December 1, 2009 at 9:50 a.m. ET. Both meetings are being held in New York City.

About Chimerix

Chimerix, Inc., is developing antiviral therapeutics to treat life-threatening diseases. Led by a world-class antiviral drug development team, Chimerix is advancing programs to address cytomegalovirus (CMV), BK virus, smallpox, human immunodeficiency virus (HIV), hepatitis C virus (HCV), respiratory syncytial virus (RSV) and influenza. The company's lead compound, CMX001, is currently in Phase 1 and 2 clinical studies for the treatment of BK virus and CMV, potentially deadly infections among immunocompromised patients. CMX001 is also being evaluated for use as a biodefense countermeasure in the event of a smallpox release. Chimerix has received financing from leading venture capital firms, including Canaan Partners, Alta Partners, Sanderling Ventures, Frazier Healthcare Ventures and Asset Management Company, in addition to U.S. Government grants. Additional information about Chimerix and its antiviral drug development programs may be found online at http://www.chimerix-inc.com.

SOURCE Chimerix, Inc.


'/>"/>
SOURCE Chimerix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Chimerix Updates the World Health Organization and the Global Health Security Initiative on Development of CMX001 as a Broad-Spectrum Therapeutic for Smallpox
2. Chimerix Initiates a Multi-dose Clinical Trial of the Companys Lead Compound, CMX001, for the Treatment for Smallpox Infection
3. Tobira Therapeutics Announces Presentation of TBR-652 Data at European AIDS Conference
4. Trubion Announces Acceptance of Two Presentations on Its TRU-016 Product Candidate at the 2009 ASH Annual Meeting
5. Onyx Pharmaceuticals to Present at the Lazard Capital Markets 6th Annual Healthcare Conference
6. Webcast Alert: Isis Pharmaceuticals and Genzyme Corporation to Present Mipomersen Phase 3 Data in HoFH During AHA
7. Hologic to Present at NASDAQ OMX 23rd Investor Program in London
8. Accera, Inc. To Present at Lazard Capital Markets 6th Annual Healthcare Conference
9. Abaxis, Inc. to Present at the Sidoti & Company Second Annual New York Institutional Investor Forum
10. CryoLife to Present at Upcoming Investor Conferences in New York
11. Keryx Biopharmaceuticals Announces Poster Presentation Highlighting Clinical Activity of KRX-0401 (Perifosine) at the 51st Annual Meeting of the American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... 2, 2017  Eli Lilly and Company (NYSE: ... the third quarter of 2017 on Tuesday, October 24, ... that day with the investment community and media to ... conference call will begin at 9 a.m. Eastern time. ... live webcast of the conference call through a link ...
(Date:9/28/2017)... Cohen Veterans Bioscience and Early Signal Foundation ... and home sensors for real-time monitoring of patients with ... nonprofit organization focused on disruptive health solutions for rare ... system to record and integrate behavioral, cognitive, physiological and ... ...
(Date:9/23/2017)... Janssen Biotech, Inc. (Janssen) announced today that ... U.S. Food and Drug Administration (FDA) for the Biologics ... treatment of moderately to severely active rheumatoid arthritis (RA). ... needed to further evaluate the safety of sirukumab in ... "We are disappointed ...
Breaking Medicine Technology:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... will be giving viewers the lowdown on sciatica in a new episode of ... that focuses on current events and innovation and investigates each subject in-depth with ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the Christian history of ... Brink” is the creation of published author, William Nowers. Captain Nowers and his ... veteran, he spent thirty years in the Navy. Following his career as a ...
(Date:10/12/2017)... Orleans, LA (PRWEB) , ... October 12, 2017 , ... ... centers in the U.S., announced today its plans to open a flagship location in ... will occupy the former Rooms To Go store next to Office Depot in the ...
(Date:10/12/2017)... Bethesda, MD (PRWEB) , ... October 12, 2017 , ... ... Award of Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s ... 4 – 8. , In honor of Morris F. Collen, a pioneer in the ...
(Date:10/12/2017)... ... October 12, 2017 , ... Dr. Parsa Mohebi, ... a medical article to the newly revamped Cosmetic Town journal section, ... hair transplant procedure known as Follicular Unit Extraction (FUE). , Dr. ...
Breaking Medicine News(10 mins):